Investigational drug · Phase 3
DT120
Also called: MM120, lysergide tartrate, LSD D-Tartrate
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Generalized Anxiety Disorder, Major Depressive Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
6
Any phase or sponsor naming "DT120"
First trial start
2024
Dec 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DT120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Anxiety Disorder
- Major Depressive Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "DT120" as an intervention, largest first.
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)Pivotal-lookingActive, not recruiting
Definium Therapeutics US, Inc.Industry
NCT06809595 · 245 participants · Start Jan 29, 2025 · Primary completion Aug 13, 2026
Drug: DT120 · For: Generalized Anxiety Disorder
Sites: Little Rock, Arkansas; Los Angeles, California; Bradenton, Florida · 36 sites in all
- A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)Pivotal-lookingActive, not recruiting
Definium Therapeutics US, Inc.Industry
NCT06741228 · 214 participants · Start Dec 11, 2024 · Primary completion Jul 15, 2026
Drug: DT120 · For: Generalized Anxiety Disorder
Sites: Gilbert, Arizona; Scottsdale, Arizona; La Jolla, California · 34 sites in all
- A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsPivotal-lookingCompleted
Definium Therapeutics US, Inc.Industry
NCT05407064 · 198 participants · Start Aug 24, 2022 · Primary completion Oct 6, 2023
Drug: MM120 · For: Anxiety Generalized
Sites: Little Rock, Arkansas; Irvine, California; La Jolla, California · 22 sites in all
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)Pivotal-lookingRecruiting
Definium Therapeutics US, Inc.Industry
NCT07592689 · 165 participants (planned) · Start May 10, 2026 · Primary completion Sep 2027
Drug: DT120 · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Orange, California; San Diego, California · 26 sites in all
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)Pivotal-lookingActive, not recruiting
Definium Therapeutics US, Inc.Industry
NCT06941844 · 149 participants · Start Apr 14, 2025 · Primary completion May 20, 2026
Drug: DT120 · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; La Jolla, California; Santa Monica, California · 22 sites in all
Definium Therapeutics US, Inc.Industry
NCT05200936 · 53 participants · Start Dec 17, 2021 · Primary completion Nov 6, 2023
Drug: MM120 · For: ADHD; Attention Deficit Disorder
Sites: Maastricht, Netherlands; Basel, Switzerland
Newest research
PubMed records naming it or its code names, newest first.
- DT120 (MM120): a single-dose orally disintegrating formulation of lysergide tartrate for generalized anxiety disorder.
Cubaa WJ · Expert Rev Neurother 2026
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Acute anxiety states in emergency neuropsychiatry: diagnostic boundaries, time-sensitive mechanisms, and rapid-acting therapeutic strategies.
Wei Y, Shi Z, Shen Y · Expert Rev Neurother 2026
- Psychedelics in psychiatry: comparative effectiveness, implementation, commercialization and safety lessons learned from intranasal esketamine.
McIntyre RS · Expert Opin Drug Saf 2026
- Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.
Robison R, Barrow R, Conant C, et al. · JAMA 2025
- Frictional forces in stent retriever procedures: The impact of vessel diameter, angulation, and deployment position.
Tsuto K, Takeuchi M, Shimizu Y, et al. · Surg Neurol Int 2024
Also in development for Generalized Anxiety Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- BuagafuranPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Buagafuran mimicPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Toludesvenlafaxine Hydrochloride Sustained-releasePhase 31 trial
Luye Pharma Group Ltd. · Generalized Anxiety Disorder
- ENX-102ENX-102 -dose, ENX-102 mid-dosePhase 23 trials
Engrail Therapeutics INC · General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder
- RE104Phase 23 trials
Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression
- CYB004Phase 21 trial
Cybin IRL Limited · Generalized Anxiety Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.